L’Oréal acquires Medik8 to expand its skincare portfolio 

UK – L’Oréal Groupe has revealed its move to acquire a majority stake in the British skincare brand Medik8, solidifying its expansion into the premium skincare market. 

The newly signed agreement underscores L’Oréal’s strategic focus on innovative and high-performance beauty solutions.

However, Inflexion, a prominent European mid-market private equity firm, which acquired Medik8 in 2021, will retain a minority stake in the company as part of the transaction, ensuring its continued involvement in the company’s future development.

In addition, Elliot Isaacs, the founder of Medik8, will retain his position on the board, while the existing management committee will stay in place to maintain operational stability and continuity.

Cyril Chapuy, President of L’Oréal LUXE, stated, “As a premium skincare range, with high levels of proven efficacy at an accessible price point, Medik8 perfectly complements our existing skincare portfolio.” 

“We share a strong belief in Medik8’s global potential and are excited to embark on this journey together to build a powerful and impactful brand presence worldwide.” 

The acquisition aligns with L’Oréal’s broader strategy of strengthening its Luxe portfolio, which includes premium skincare brands such as La Roche-Posay, CeraVe, and SkinCeuticals. 

The company’s Dermatological Beauty Division, which generated over €7 billion(USD 7.97 billion) in revenue in 2024, has been its fastest-growing segment, reflecting the increasing consumer preference for science-driven skincare.

Founded in 2009, Medik8 has built a strong reputation for its Vitamin A-based skincare solutions, particularly its Crystal Retinal serum and CSA Philosophy, a regimen that emphasises vitamin C and sunscreen during the day and Vitamin A at night. 

The brand has cultivated a loyal customer base through its ingredient-led approach, blending professional-grade formulations with accessibility.

According to L’Oréal, the transaction is expected to be finalized in the coming months, pending receipt of regulatory approvals and fulfilment of standard closing conditions. 

Once completed, L’Oréal will begin consolidating Medik8’s sales, further integrating the brand into its global distribution network.

L’Oréal’s acquisition of Medik8 follows a series of strategic investments, including the recent purchase of Korean beauty brand Dr. G. 

Dr.G is recognized for its ingredient-led skincare, including the best-selling R.E.D Blemish Clear Soothing Cream, and ranks among South Korea’s top three mass-market and dermocosmetic brand.

Sign up to receive our email newsletters with the latest news updates and insights from Africa and the World HERE.